Partners

The FinnGen research project involves all the same actors as drug development: universities, hospitals, biobanks and pharmaceutical companies. With this open cooperation, we hope to speed up the emergence of new innovations.

Coordinating organizations:

University of Helsinki (Institute for Molecular Medicine Finland, FIMM) is coordinating the FinnGen study. Helsinki Biobank (the Hospital District of Helsinki and Uusimaa) coordinates the sample collection and THL acts as the data controller of the register data.

Funded by:

and the funding research partners:

AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Squibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.

In cooperation with the Finnish Biobank cooperative FINBB and these Finnish biobanks:

Auria Biobank

• Wellbeing Services County of Southwest Finland
• University of Turku

Northern Finland Biobank Borealis

• Wellbeing Services County of North Ostrobothnia
• University of Oulu

Arctic Biobank

• University of Oulu

Central Finland Biobank

• Wellbeing Services County of Central Finland
• University of Jyväskylä

Finnish Clinical Biobank Tampere

• Wellbeing Services County of Pirkanmaa
• Tampere University Foundation sr

Biobank of Eastern Finland

• Wellbeing Services County of North Savo
• University of Eastern Finland

Helsinki Biobank

• HUS Group, the joint authority for Helsinki and Uusimaa

THL Biobank

• The Finnish Institute for Health and Welfare

FRC Blood Service Biobank

• The Finnish Red Cross Blood Service

Finnish Hematology Registry and Clinical Biobank

Finnish Biobank Cooperative (FINBB)

The host organisations of the above listed biobanks are described here.